Globus Medical: Healthcare's Bright Spot

Healthcare Stocks: Globus Medical Shines Amidst Post-COVID Hiccups Healthcare stocks have underperformed, with Globus Medical standing out. Despite post-COVID challenges, Globus has seen 3.7% growth over six months, while the S&P 500 climbed 7.1%. Globus operates in 64 countries, launched 10 new products last year, and boasts 30.3% annual revenue growth over 5 years. Its earnings per share compound at 22.2%, outpacing peers. Trading at $78.81 and 17.8 times forward P/E, Globus is poised for success, regardless of economic conditions. Meanwhile, Privia Health and Collegium Pharmaceutical face hurdles, with Privias small scale and Collegiums cost issues impacting profitability. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2db93aacebf37d43